Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhejiang Shengda Bio-Pharm Co's EV-to-FCF or its related term are showing as below:
SHSE:603079'
s EV-to-FCF Range Over the Past 10 Years
Min: -728.57 Med: -22.24 Max: 320.51
Current: 125.82
During the past 13 years, the highest EV-to-FCF of Zhejiang Shengda Bio-Pharm Co was 320.51. The lowest was -728.57. And the median was -22.24.
SHSE:603079's EV-to-FCF is ranked worse than 89.63% of 569
companies
in the Drug Manufacturers industry
Industry Median: 20.47
vs SHSE:603079: 125.82
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Shengda Bio-Pharm Co (SHSE:603079) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Shengda Bio-Pharm Co's PE Ratio (TTM) for today is calculated as:
Zhejiang Shengda Bio-Pharm Co's share price for today is ¥10.56.
Zhejiang Shengda Bio-Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.290.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zhejiang Shengda Bio-Pharm Co EV-to-FCF Related Terms
Zhejiang Shengda Bio-Pharm Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Zhejiang Shengda Bio-Pharm Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Shengda Bio-Pharm Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Zhejiang Shengda Bio-Pharm Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zhejiang Shengda Bio-Pharm Co's EV-to-FCF falls into.
Zhejiang Shengda Bio-Pharm Co's current Enterprise Value is ¥1,745.0 Mil.
Zhejiang Shengda Bio-Pharm Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥14.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Shengda Bio-Pharm Co (SHSE:603079) has a EV-to-FCF of 124.74 as of Jul. 28, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Shengda Bio-Pharm Co and its competitors. According to the industry distribution chart, Zhejiang Shengda Bio-Pharm Co ranks #510 out of 569 companies in the Drug Manufacturers industry, placing it in the top 89.6%.
Is Zhejiang Shengda Bio-Pharm Co's EV-to-FCF too high?
Zhejiang Shengda Bio-Pharm Co's current EV-to-FCF is 124.74. The Drug Manufacturers industry median EV-to-FCF is 20.47. Zhejiang Shengda Bio-Pharm Co's value of 124.74 is 509.4% above this industry median. Based on the distribution chart, Zhejiang Shengda Bio-Pharm Co ranks #510 out of 569 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Zhejiang Shengda Bio-Pharm Co has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Shengda Bio-Pharm Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Zhejiang Shengda Bio-Pharm Co ranks #510 out of 569 companies for EV-to-FCF. This places Zhejiang Shengda Bio-Pharm Co in the lower half of its industry. The industry median EV-to-FCF is 20.47. Zhejiang Shengda Bio-Pharm Co's value of 124.74 is 509.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.47, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Shengda Bio-Pharm Co's current EV-to-FCF of 124.74 is 509.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Shengda Bio-Pharm Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Shengda Bio-Pharm Co's current EV-to-FCF is 124.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Shengda Bio-Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Shengda Bio-Pharm Co (SHSE:603079) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥14.40, compared to a current price of ¥10.56 — trading 26.7% below its estimated fair value. The current EV-to-FCF is 124.74 and 509.4% above the Drug Manufacturers industry median of 20.47. Zhejiang Shengda Bio-Pharm Co's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zhejiang Shengda Bio-Pharm Co (SHSE:603079), the current EV-to-FCF is 124.74 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Shengda Bio-Pharm Co (SHSE:603079) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Shengda Bio-Pharm Co stock appears to be undervalued.
The current stock price of ¥10.56 is trading 26.7% below its estimated GF Value™ of ¥14.40.
GuruFocus considers Zhejiang Shengda Bio-Pharm Co to be Modestly Undervalued.
Key valuation signals for SHSE:603079:
EV-to-FCF: 124.74
GF Value™: ¥14.40 vs. price of ¥10.56 (26.7% below fair value)
Industry Position: 509.4% above the Drug Manufacturers median (#510 of 569)
No single metric tells the full story. See the SHSE:603079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Shengda Bio-Pharm Co Business Description
Zhejiang Shengda Bio-Pharm Co Ltd is a pharmaceutical company. It is mainly engaged in the research and development, and production of biotin and biological preservatives. Its product portfolio includes biotin, folic acid, and other vitamin products, nisin, natamycin, and sucrose fermentation products.
61GF Score
Get the complete analysis for SHSE:603079
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603079 has been successfully added to your 
